Lincoln Pharma H1 Net Jumps 20% to Rs 57.5 Cr, Q2 Profit at Rs 20.84 Cr

New Delhi: Drug firm Lincoln Pharmaceuticals on Thursday a consolidated net profit of Rs 20.84 crore for the September quarter, while its first half profit surged by 20 per cent to Rs 57.50 crore.

The company had posted a net profit of Rs 20.01 crore in the July-“September period of the previous fiscal, Lincoln Pharmaceuticals said in a regulatory filing.

Total income for the second quarter rose 17.75 per cent to Rs 200.88 crore, compared to Rs 170.60 crore in the year-ago period.

For the first half of the ongoing fiscal (H1 FY27), the company’s consolidated net profit grew by 20 per cent to Rs 57.50 crore against Rs 47.71 crore in H1 FY26. Total income in H1 rose 18.39 per cent to Rs 402.43 crore from Rs 339.93 crore a year ago.

Commenting on the results, Lincoln Pharmaceuticals Director Munjal Patel said: “We are pleased to report another strong quarter… In FY27, we will continue to evaluate opportunities to expand our presence across domestic and international markets, leveraging our enhanced manufacturing capabilities and robust product pipeline.”

The company said it is targeting a revenue of Rs 1,000 crore over the next three years as part of its broader strategy to achieve an annual growth rate of 15-18 per cent.

Lincoln Pharma also plans to expand its global export footprint from over 60 countries to 90 countries over the next two to three years, supported by recent approvals from Australia’s TGA, EU GMP, and its entry into the Canadian market.

(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)